Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Comment by RICHOFFMBXon Dec 19, 2024 3:13pm
120 Views
Post# 36370903

RE:E-MAIL TO CAMERON GROOME (CEO) - JIM CURRIE (CFO)

RE:E-MAIL TO CAMERON GROOME (CEO) - JIM CURRIE (CFO)I'm just a hack, but I don't think you can point fingers at any one entity for holding the price down? They're only selling >$25K worth, after all.  Volume and eyes-on this stock has always been fairly dismal. Even with continued positive and record-breaking earnings, I feel like we won't rocket until Kinlytic is close to market, breaking the current monopoly into a duopoly.

I do wonder what we'd look like if, instead of employee stock options, employees were just paid more and we continued the share buyback.

Regardless, watching Cameron and crew speak, share their plans and realize them one-by-one continues to inspire confidence.  

Thesis is unchanged. I'll continue to load up until this rocket ship takes off.
<< Previous
Bullboard Posts
Next >>